Dong-E-E-Jiao Co Ltd

Dong-E-E-Jiao maintains a strong liquidity position, with a current ratio of 4.65, indicating the company can easily cover its short-term liabilities with its short-term assets. The company has a negligible debt-to-equity ratio of 0.0, suggesting it is not reliant on debt financing and has a conservative capital structure. However, the risk assessment notes that net cash is negative after subtracting total debt, which could signal potential liquidity constraints if cash flow from operations were to decline.

Profitability metrics show a return on equity (ROE) of 3.76% and a return on assets (ROA) of 3.08%. These figures are below the typical thresholds for high-performing pharmaceutical firms, suggesting that the company is generating modest returns relative to its equity and asset base. The gross profit margin is 74.2%, which is in line with industry norms, but the operating margin of 36.2% and net margin of 29.7% indicate that the company is managing to maintain profitability despite rising costs.

The company's revenue is primarily concentrated in its core TCM product line, with a significant portion of sales derived from domestic markets in China. There is no indication of substantial international revenue or diversification into other therapeutic areas. This concentration could expose the company to regulatory and market risks specific to the Chinese pharmaceutical sector.

Looking ahead, the company is expected to maintain a stable growth trajectory, with revenue and earnings likely to remain flat or grow modestly. The capital expenditure of -42.28 million CNY suggests that the company is not investing heavily in new projects or infrastructure, which may limit long-term growth potential. The outlook for the next fiscal year is neutral, with no significant changes expected in the company's financial performance.

The risk assessment highlights a medium liquidity risk, primarily due to the negative net cash position after accounting for total debt. While the company has a low dilution risk, the absence of a strong growth strategy and limited diversification could pose challenges in the long term. The company has not issued new shares recently, and there is no indication of dilution pressure in the near term.

Recent investor relations data shows a generally positive sentiment, with a mean recommendation of 1.78 (on a scale of 1 to 5, where 1 is "strong buy"). Analysts have set a mean price target of 74.69 CNY, with a median of 75.00 CNY. The absence of "hold" or "sell" ratings suggests that the market is cautiously optimistic about the company's prospects, though not overly bullish.

Dong-E-E-Jiao Co Ltd (000423.SZ) has undergone a significant update to its corporate taxonomy, now formally classified under the "Pharmaceuticals & Medical Research" activity within the broader "Healthcare" economic sector. This reclassification represents a medium-severity change in the company's profile, establishing a clearer framework for understanding its operational focus and industry alignment. Alongside the sectoral update, the company's risk assessment profile has been initialized with specific metrics. Dilution risk is now assessed as "low," indicating a stable capital structure with minimal threat of share value erosion from new issuances. This assessment provides investors with greater confidence regarding the preservation of existing equity value. Conversely, liquidity risk has been categorized as "medium." This designation suggests that while the company maintains operational stability, there may be moderate constraints or considerations regarding the ease of converting assets to cash or managing short-term obligations. This balanced risk view complements the low dilution assessment, offering a nuanced picture of the firm's financial health. The company's current profile reflects a lean organizational structure, with only two officers listed and no analyst coverage, index memberships, or top holders recorded in the available data. This lack of external market participation metrics, combined with the newly defined sector and risk parameters, highlights a company that is operationally focused but currently lacks broad institutional visibility or active market tracking.

Revenue grew at a 14.9% CAGR over four years, demonstrating strong top-line expansion momentum.

Net income surged with a 41.0% CAGR, significantly outpacing revenue growth and indicating robust profitability.

Operating and net margins are best-in-class compared to the pharmaceutical cohort median.

Analysts project 54.9% upside to the mean price target, reflecting strong market confidence.

The company maintains a zero debt-to-equity ratio, providing a pristine balance sheet with minimal leverage risk.

Free cash flow turned negative in FY2025, signaling potential liquidity pressures or increased capital requirements.

Return on equity remains low at 3.76%, suggesting inefficient use of shareholder capital despite high margins.

Medium liquidity risk flags suggest potential challenges in meeting short-term financial obligations.

Revenue ¥1.81B, +5,5% YoY; Operating income +7,2% YoY.

• ▍Revenue ¥1.81B, +5,5% YoY
• ▍Operating income +7,2% YoY
• ▍Net income +7,1% YoY
• ▍Net margin 25.1%

Revenue ¥1.93B, +5,8% YoY; Operating income +11,7% YoY.

• ▍Revenue ¥1.93B, +5,8% YoY
• ▍Operating income +11,7% YoY
• ▍Net income +14,8% YoY
• ▍Net margin 24.0%

Revenue ¥1.72B, +8,5% YoY; Operating income +13,6% YoY.

• ▍Revenue ¥1.72B, +8,5% YoY
• ▍Operating income +13,6% YoY
• ▍Net income +10,3% YoY
• ▍Net margin 26.6%

Revenue ¥1.33B, +2,9% YoY; Operating income +0,4% YoY.

• ▍Revenue ¥1.33B, +2,9% YoY
• ▍Operating income +0,4% YoY
• ▍Net income +2,0% YoY
• ▍Net margin 29.5%

Revenue ¥1.72B; Operating income ¥507.7M.

• ▍Revenue ¥1.72B
• ▍Operating income ¥507.7M
• ▍Net margin 24.7%

Revenue ¥1.83B; Operating income ¥506.3M.

• ▍Revenue ¥1.83B
• ▍Operating income ¥506.3M
• ▍Net margin 22.2%

Revenue ¥1.58B; Operating income ¥463.9M.

• ▍Revenue ¥1.58B
• ▍Operating income ¥463.9M
• ▍Net margin 26.2%

Revenue ¥1.29B; Operating income ¥468.8M.

• ▍Revenue ¥1.29B
• ▍Operating income ¥468.8M
• ▍Net margin 29.7%

Revenue ¥6.70B, +8,8% YoY; Operating income +12,0% YoY.

• ▍Revenue ¥6.70B, +8,8% YoY
• ▍Operating income +12,0% YoY
• ▍Net income +11,7% YoY
• ▍Free cash flow +150,7% YoY
• ▍Net margin 25.9%

Revenue ¥6.16B, +30,6% YoY; Operating income +36,0% YoY.

• ▍Revenue ¥6.16B, +30,6% YoY
• ▍Operating income +36,0% YoY
• ▍Net income +35,3% YoY
• ▍Free cash flow −164,7% YoY
• ▍Net margin 25.3%

Revenue ¥4.72B, +16,7% YoY; Operating income +48,7% YoY.

• ▍Revenue ¥4.72B, +16,7% YoY
• ▍Operating income +48,7% YoY
• ▍Net income +47,5% YoY
• ▍Free cash flow +4,3% YoY
• ▍Net margin 24.4%

Revenue ¥4.04B, +5,0% YoY; Operating income +61,7% YoY.

• ▍Revenue ¥4.04B, +5,0% YoY
• ▍Operating income +61,7% YoY
• ▍Net income +77,1% YoY
• ▍Free cash flow +27,5% YoY
• ▍Net margin 19.3%